IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Wall Str
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Form 8-K Inhibikase Therapeutics, For: Dec 19
Form 424B5 Inhibikase Therapeutics,
Form 4 Inhibikase Therapeutics, For: Nov 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
Form 8-K Inhibikase Therapeutics, For: Nov 20
Form 424B5 Inhibikase Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.